A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DOSE-RANGING STUDY TO EVALUATE LEBRIKIZUMAB (MILR1444A) IN ADULT PATIENTS WITH ASTHMA WHO ARE NOT TAKING INHALED CORTICOSTEROIDS (MOLLY)

Update Il y a 4 ans
Reference: EUCTR2009-013267-19

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The main objectives of this study are as follows; - To evaluate the efficacy of different doses of lebrikizumab compared with placebo as measured by relative change in pre-bronchodilator FEV1. - To evaluate the safety and tolerability of different doses of lebrikizumab.


Inclusion criteria

  • Asthma in adult patients not taking inhaled corticosteroids

Links